L Idolazzi1, M Rossini2, O Viapiana2, V Braga2, A Fassio2, C Benini2, V Kunnathully2, S Adami2, D Gatti2. 1. Rheumatology Unit - Department of Medicine, University of Verona, Piazzale A. Stefani 1, 37126, Verona, VR, Italy. luca.idolazzi@univr.it. 2. Rheumatology Unit - Department of Medicine, University of Verona, Piazzale A. Stefani 1, 37126, Verona, VR, Italy.
Abstract
Several therapies are available for osteoporis. Understanding the bone turnover changes and their mutual realtionship gives an overall view and might lead to a target therapy INTRODUCTION: The aim of this study is to compare the changes in bone turnover markers in patients treated with either denosumab alone, teriparatide (TPTD) alone, or in a third therapeutic scheme, when TPTD was added to patients previously treated with denosumab. METHODS: Fifty-nine women over 65 years old with severe postmenopausal osteoporosis (evidence of at least two moderate-severe vertebral fractures) were enrolled in the study. Serum samples were collected every 3 months. They were assayed for intact N-propeptide of type I collagen (P1NP), C-terminal telopeptide of type I collagen (CTX), intact parathyroid hormone (PTH), 25 hydroxy-vitamin D (25 OHD), Sclerostin (SOST), and Dickkopf-related protein 1 (DKK1). Bone mass density was assessed by dual-energy X-ray absorptiometry at the lumbar spine and at the total hip. RESULTS: In the groups treated only with TPTD or with denosumab, bone turnover markers increased and decreased, respectively. In TPTD group, a later significant increase in DKK1 was observed, while in denosumab group, a progressive increase in SOST was associated with a progressive significant decrease in DKK1. In the group treated first with denosumab and in which TPTD was added 3 months later, both CTX and P1NP increased 3 months after the beginning of TPTD. The strong effect of denosumab on bone turnover seems to be reversed by TPTD treatment. CONCLUSIONS: In this study, we showed that TPTD is able to express its biological activity even when bone turnover is fully suppressed by denosumab treatment. The combination therapy is associated with significant increases in both DKK1 and SOST.
Several therapies are available for osteoporis. Understanding the bone turnover changes and their mutual realtionship gives an overall view and might lead to a target therapy INTRODUCTION: The aim of this study is to compare the changes in bone turnover markers in patients treated with either denosumab alone, teriparatide (TPTD) alone, or in a third therapeutic scheme, when TPTD was added to patients previously treated with denosumab. METHODS: Fifty-nine women over 65 years old with severe postmenopausal osteoporosis (evidence of at least two moderate-severe vertebral fractures) were enrolled in the study. Serum samples were collected every 3 months. They were assayed for intact N-propeptide of type I collagen (P1NP), C-terminal telopeptide of type I collagen (CTX), intact parathyroid hormone (PTH), 25 hydroxy-vitamin D (25 OHD), Sclerostin (SOST), and Dickkopf-related protein 1 (DKK1). Bone mass density was assessed by dual-energy X-ray absorptiometry at the lumbar spine and at the total hip. RESULTS: In the groups treated only with TPTD or with denosumab, bone turnover markers increased and decreased, respectively. In TPTD group, a later significant increase in DKK1 was observed, while in denosumab group, a progressive increase in SOST was associated with a progressive significant decrease in DKK1. In the group treated first with denosumab and in which TPTD was added 3 months later, both CTX and P1NP increased 3 months after the beginning of TPTD. The strong effect of denosumab on bone turnover seems to be reversed by TPTD treatment. CONCLUSIONS: In this study, we showed that TPTD is able to express its biological activity even when bone turnover is fully suppressed by denosumab treatment. The combination therapy is associated with significant increases in both DKK1 and SOST.
Authors: Yanfei L Ma; Qingqiang Zeng; David W Donley; Louis-Georges Ste-Marie; J Christopher Gallagher; Gail P Dalsky; Robert Marcus; Erik Fink Eriksen Journal: J Bone Miner Res Date: 2006-06 Impact factor: 6.741
Authors: Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty Journal: Dev Cell Date: 2005-05 Impact factor: 12.270
Authors: Felicia Cosman; Erik Fink Eriksen; Chris Recknor; Paul D Miller; Núria Guañabens; Christian Kasperk; Philemon Papanastasiou; Aimee Readie; Hanumantha Rao; Jürg A Gasser; Christina Bucci-Rechtweg; Steven Boonen Journal: J Bone Miner Res Date: 2011-03 Impact factor: 6.741
Authors: Benjamin Z Leder; Joy N Tsai; Alexander V Uihlein; Sherri-Ann M Burnett-Bowie; Yuli Zhu; Katelyn Foley; Hang Lee; Robert M Neer Journal: J Clin Endocrinol Metab Date: 2014-02-11 Impact factor: 5.958
Authors: Felicia Cosman; Robert A Wermers; Christopher Recknor; Karen F Mauck; Li Xie; Emmett V Glass; John H Krege Journal: J Clin Endocrinol Metab Date: 2009-07-07 Impact factor: 5.958
Authors: Fatma Gossiel; Jessica R Scott; Margaret A Paggiosi; Kim E Naylor; Eugene V McCloskey; Nicola F A Peel; Jennifer S Walsh; Richard Eastell Journal: J Clin Endocrinol Metab Date: 2018-04-01 Impact factor: 5.958
Authors: Bowen Wang; Zehai Wang; Atharva A Poundarik; Mohammed J Zaki; Richard S Bockman; Benjamin S Glicksberg; Girish N Nadkarni; Deepak Vashishth Journal: J Clin Endocrinol Metab Date: 2022-03-24 Impact factor: 5.958